期刊文献+

Assessment of hepatic VX_2 tumors with combined percutaneous transhepatic lymphosonography and contrast-enhanced ultrasonographic imaging 被引量:1

Assessment of hepatic VX_2 tumors with combined percutaneous transhepatic lymphosonography and contrast-enhanced ultrasonographic imaging
下载PDF
导出
摘要 AIM: To evaluate the feasibility and efficacy of percutaneous transhepatic lymphosonography (PTL) as a novel method for the detection of tumor lymphangiogenesis in hepatic VX2 of rabbits and to evaluate combined PTL and routine contrast-enhanced ultrasonographic imaging for the diagnosis of liver cancer. METHODS: Ten rabbits with VX2 tumor were included in this study. SonoVue (0.1 mL/kg) was injected into each rabbit via an ear vein for contrast-enhanced ultrasonographic imaging, and 0.5 mL SonoVue was injected into the normal liver parenchyma near the VX2 tumor for PTL. Images and/or movie clips were stored for further analysis. RESULTS: UItrasonographic imaging showed VX2 tumors ranging 5-19 mm in the liver of rabbits. The VX2 tumor was hyperechoic and hypoechoic to liver parenchyma at the early and later phase, respectively. The hepatic lymph vessels were visualized immediately after injection of contrast medium and continuously vi- sualized with SonoVue during PTL. The boundaries of VX2 tumors were hyperechoic to liver parenchyma and the tumors. There was a significant difference in the values for the boundaries of VX2 tumors after injection compared with the liver normal parenchyma and the tumor parenchyma during PTL.CONCLUSION: PTL is a novel method for the detection of tumor lymphangiogenesis in hepatic VX2 of rabbits. Combined PTL and contrast-enhanced ultrasonographic imaging can improve the diagnosis of liver cancer. AIM: To evaluate the feasibility and efficacy of per-cutaneous transhepatic lymphosonography (PTL) as a novel method for the detection of tumor lymphan-giogenesis in hepatic VX2 of rabbits and to evaluate combined PTL and routine contrast-enhanced ultraso-nographic imaging for the diagnosis of liver cancer. METHODS: Ten rabbits with VX2 tumor were included in this study. SonoVue (0.1 mL/kg) was injected into each rabbit via an ear vein for contrast-enhanced ul-trasonographic imaging,and 0.5 mL SonoVue was injected into the normal liver parenchyma near the VX2 tumor for PTL. Images and/or movie clips were stored for further analysis. RESULTS: Ultrasonographic imaging showed VX2 tumors ranging 5-19 mm in the liver of rabbits. The VX2 tumor was hyperechoic and hypoechoic to liver parenchyma at the early and later phase,respectively. The hepatic lymph vessels were visualized immediately after injection of contrast medium and continuously vi-sualized with SonoVue during PTL. The boundaries of VX2 tumors were hyperechoic to liver parenchyma and the tumors. There was a signifi cant difference in the values for the boundaries of VX2 tumors after injection compared with the liver normal parenchyma and the tumor parenchyma during PTL.CONCLUSION: PTL is a novel method for the detec-tion of tumor lymphangiogenesis in hepatic VX2 of rabbits. Combined PTL and contrast-enhanced ultraso-nographic imaging can improve the diagnosis of liver cancer.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第24期3908-3913,共6页 世界胃肠病学杂志(英文版)
基金 Beijing Municipal Natural Science Foundation,No.7082084
  • 相关文献

参考文献40

  • 1[1]Maruyama H,Matsutani S,Saisho H,Mine Y,Kamiyama N,Hirata T,Sasamata M.Real-time blood-pool images of contrast enhanced ultrasound with Definity in the detection of tumour nodules in the liver.Br J Radiol 2005; 78:512-518
  • 2[2]McDonald DM,Choyke PL.Imaging of angiogenesis:from microscope to clinic.Nat Med 2003; 9:713-725
  • 3[3]Stewart VR,Sidhu PS.New directions in ultrasound:microbubble contrast.Br J Radiol 2006; 79:188-194
  • 4[4]Bloch SH,Dayton PA,Ferrara KW.Targeted imaging using ultrasound contrast agents.Progess and opportunities for clinical and research applications.IEEE Eng Med Biol Mag 2004; 23:18-29
  • 5[5]Nicolau C,Catala V,Vilana R,Gilabert R,Bianchi L,Sole M,Pages M,Bru C.Evaluation of hepatocellular carcinoma using SonoVue,a second generation ultrasound contrast agent:correlation with cellular differentiation.Eur Radiol 2004; 14:1092-1099
  • 6[6]Cosgrove D.Future prospects for SonoVue and CPS.Eur Radiol 2004; 14 Suppl 8:P116-P124
  • 7[7]Hettiarachchi K,Talu E,Longo ML,Dayton PA,Lee AP.On-chip generation of microbubbles as a practical technology for manufacturing contrast agents for ultrasonic imaging.Lab Chip 2007; 7:463-468
  • 8[8]Zhao S,Kruse DE,Ferrara KW,Dayton PA.Selective imaging of adherent targeted ultrasound contrast agents.Phys Med Biol 2007; 52:2055-2072
  • 9[9]Lindner JR.Microbubbles in medical imaging:current applications and future directions.Nat Rev Drug Discov 2004; 3:527-532
  • 10[10]Zhang XH,Huang DP,Guo GL,Chen GR,Zhang HX,Wan L,Chen SY.Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.BMC Cancer 2008; 8:4

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部